Enrollment complete in clinical trial of nalbuphine ER for IPF cough
Enrollment is now complete in a Phase 2b clinical trial, dubbed CORAL, that’s testing nalbuphine extended-release (ER) tablets — planned to be marketed as Haduvio — in people with idiopathic pulmonary fibrosis (IPF) who experience chronic cough. That achievement was announced by Trevi Therapeutics, the U.S. company…